Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -755.65 Million | -502.73 Million | -481.16 Million | -290.27 Million | -334.77 Million | -204.56 Million |
| Net Income | -831.72 Million | -611.13 Million | -548.28 Million | -422.8 Million | -359.66 Million | -246.49 Million |
| Depreciation & Amortization | 10.73 Million | 12.05 Million | 8.6 Million | 7.66 Million | 7.46 Million | 1.83 Million |
| Deferred income taxes | -60.63 Million | -58.22 Million | -56.62 Million | - | - | - |
| Stock-based compensation | 60.63 Million | 58.22 Million | 56.62 Million | 43.34 Million | 7.24 Million | 16.07 Million |
| Change in working capital | 11.43 Million | 21.43 Million | 2.88 Million | 81.27 Million | 10.74 Million | 28.7 Million |
| Other non-cash items | 53.89 Million | 74.91 Million | 55.62 Million | 243 Thousand | -556 Thousand | 11.39 Million |
| Investing Cash Flow | -284 Thousand | 229.31 Million | -2.39 Million | 182.53 Million | 85.78 Million | -387.47 Million |
| Investments in PPE | -284 Thousand | -3.33 Million | -2.39 Million | -294 Thousand | -3.42 Million | -2.49 Million |
| Acquisitions | - | - | - | - | 87 Thousand | 127 Thousand |
| Investment purchases | - | - | - | - | -87 Thousand | -493.98 Million |
| Sales/Maturities of investments | - | 232.64 Million | - | 182.82 Million | 89.12 Million | 109 Million |
| Other Investing Activities | - | 232.64 Million | - | 182.82 Million | 87 Thousand | -127 Thousand |
| Financing Cash Flow | -7.54 Million | 1.11 Billion | -4.85 Million | 1.06 Billion | -8.88 Million | 450.3 Million |
| Debt repayment | -7.54 Million | -728.37 Million | -4.85 Million | -4.67 Million | -4.42 Million | -44 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 396.19 Million | - | 1.07 Billion | 3.18 Million | 471.06 Million |
| Other Financing Activities | -7.54 Million | 1.44 Billion | -4.85 Million | -1000.00 | -7.64 Million | -20.75 Million |
| Accounts receivables | -35.06 Million | -33.24 Million | -39.35 Million | -1.3 Million | -6.62 Million | 88 Thousand |
| Accounts payables | 24.48 Million | 9.11 Million | 28.57 Million | -23.89 Million | 10.14 Million | 36.65 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 22.01 Million | 45.56 Million | 13.66 Million | 106.47 Million | 7.21 Million | -8.03 Million |
| Cash at beginning of period | 1.49 Billion | 651.34 Million | 1.13 Billion | 181.69 Million | 439.44 Million | 581.07 Million |
| Cash at end of period | 732.06 Million | 1.49 Billion | 651.34 Million | 1.13 Billion | 181.69 Million | 439.44 Million |
| Capital Expenditure | -284 Thousand | -3.33 Million | -2.39 Million | -294 Thousand | -3.42 Million | -2.49 Million |
| Effect of forex changes on cash | -636 Thousand | 576 Thousand | 403 Thousand | -501 Thousand | 131 Thousand | 93 Thousand |
| Net cash flow / Change in cash | -764.11 Million | 844.83 Million | -488.02 Million | 957.66 Million | -257.74 Million | -141.63 Million |
| Free Cash Flow | -755.93 Million | -506.06 Million | -483.56 Million | -290.56 Million | -338.2 Million | -207.05 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -103.79 Million | -207.94 Million | -218.57 Million | -124.45 Million | -831.72 Million | -250.65 Million |
| Depreciation & Amortization | - | - | - | 10.73 Million | 10.73 Million | - |
| Deferred income taxes | - | - | - | -30.17 Million | -60.63 Million | - |
| Stock-based compensation | - | 9.5 Million | 13 Million | 19.43 Million | 60.63 Million | 5.8 Million |
| Change in working capital | -22.84 Million | 4.35 Million | -52.48 Million | 1.97 Million | 11.43 Million | 8.3 Million |
| Other non-cash items | -22.16 Million | 14.44 Million | 68.92 Million | -50.46 Million | 53.89 Million | 43.68 Million |
| Investing Cash Flow | - | - | -116 Thousand | 405 Thousand | -284 Thousand | - |
| Investments in PPE | - | - | -116 Thousand | 405 Thousand | -284 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -1.89 Million | 352.43 Million | -1.85 Million | -2.19 Million | -7.54 Million | -1.79 Million |
| Debt repayment | - | -1.87 Million | -1.85 Million | -2.19 Million | -7.54 Million | -1.79 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 354.3 Million | - | - | - | - |
| Other Financing Activities | -1.89 Million | 354.3 Million | - | -2.19 Million | - | -1.79 Million |
| Accounts receivables | - | - | - | -35.06 Million | -35.06 Million | - |
| Accounts payables | - | - | - | - | 24.48 Million | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -22.84 Million | 4.35 Million | -52.48 Million | 37.04 Million | 22.01 Million | 8.3 Million |
| Cash at beginning of period | 704.99 Million | 541.46 Million | 732.06 Million | 908.17 Million | 1.49 Billion | 1.1 Billion |
| Cash at end of period | 553.54 Million | 704.99 Million | 541.46 Million | 732.06 Million | 732.06 Million | 908.17 Million |
| Capital Expenditure | - | - | -116 Thousand | 405 Thousand | -284 Thousand | - |
| Effect of forex changes on cash | -762 Thousand | 242 Thousand | 523 Thousand | -1.38 Million | -636 Thousand | 329 Thousand |
| Net cash flow / Change in cash | -151.45 Million | 163.53 Million | -190.59 Million | -176.11 Million | -764.11 Million | -194.33 Million |
| Free Cash Flow | -148.8 Million | -189.14 Million | -189.25 Million | -172.54 Million | -755.93 Million | -192.86 Million |
CFF
688659
IR5B
1951
GCAN
CWXZF